 Home > Biochemistry News > Biotechnology News > Ascletis Pharma's 2nd FASN Inhibitor Approved for Treatment of Advanced Solid Tumors

Ascletis Pharma's 2nd FASN Inhibitor Approved for Treatment of Advanced Solid Tumors

 Last Update: 2022-04-17
 Source: Internet
 Author: User

Tags

sugar cube drug

marijuana smoke cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Article source: Medical Cube Info

A few days ago, CDE's official website showed that the clinical trial (IND) application of Ascletis' second fatty acid synthase (FASN) inhibitor ASC60 was approved by the Food and Drug Administration for the treatment of advanced solid tumors

Overexpression of FASN has been found in many solid and hematological tumors, including non-small cell lung cancer, breast cancer, ovarian cancer, and prostate cancer

ASC60 is a potent, selective, and safe oral small-molecule FASN inhibitor that disrupts metabolism and tumor-related signaling in tumor cells by blocking de novo fatty acid synthesis (DNL)

On March 27, Ascletis announced that the latest preclinical study results of ASC60 have been selected for the 2022 American Association for Cancer Research (AACR) annual meeting

Another clinical-stage FASN inhibitor from Ascletis is ASC40

The data showed that the ORR of ASC40 plus bevacizumab was 65%, including 20% CR and 45% PR; the 6-month progression-free survival (PFS6) was 47%, compared to the previous bevacizumab monotherapy.

In February 2019, Ascletis Pharma obtained the exclusive license for ASC40 and ASC60 in Greater China from Sagimet Biosciences

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.